SEC Comment Letter 0000000000-22-013885 to AEON Biopharma, Inc. (AEON) (CIK 0001837607) (AEON)
AEON Biopharma, Inc. (AEON) (CIK 0001837607)
Date: Dec. 23, 2022 · CIK: 0001837607 · Accession: 0000000000-22-013885
AI Filing Summary & Sentiment
File numbers found in text: 001-40021
Letter
United States securities and exchange commission logo December 23, 2022 Oleg Grodnensky Chief Operating Officer Priveterra Acquisition Corp. 300 SE 2nd Street, Suite 600 Fort Lauderdale, FL 33301 Re:Priveterra Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed December 13, 2022 File No. 001-40021 Dear Oleg Grodnensky: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Real Estate & Construction cc: W. Soren Kreider IV
Show Raw Text
United States securities and exchange commission logo
December 23, 2022
Oleg Grodnensky
Chief Operating Officer
Priveterra Acquisition Corp.
300 SE 2nd Street, Suite 600
Fort Lauderdale, FL 33301
Re:Priveterra Acquisition Corp.
Preliminary Proxy Statement on Schedule 14A
Filed December 13, 2022
File No. 001-40021
Dear Oleg Grodnensky:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc: W. Soren Kreider IV